Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Robertson JF, et al. Among authors: morris c. Cancer. 2003 Jul 15;98(2):229-38. doi: 10.1002/cncr.11468. Cancer. 2003. PMID: 12872340 Free article. Clinical Trial.
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Howell A, et al. Among authors: morris c. J Clin Oncol. 2004 May 1;22(9):1605-13. doi: 10.1200/JCO.2004.02.112. J Clin Oncol. 2004. PMID: 15117982 Clinical Trial.
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. Ranson M, et al. Among authors: morris c. J Clin Oncol. 2002 May 1;20(9):2240-50. doi: 10.1200/JCO.2002.10.112. J Clin Oncol. 2002. PMID: 11980995 Clinical Trial.
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, Lind MJ, Lee SM, Newell DR, Bleehen NM, Newlands ES, Calvert AH, Margison GP, Thatcher N. Middleton MR, et al. Among authors: morris c. Br J Cancer. 1998 Nov;78(9):1199-202. doi: 10.1038/bjc.1998.654. Br J Cancer. 1998. PMID: 9820180 Free PMC article. Clinical Trial.
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A. Board RE, et al. Among authors: morris c. Br J Cancer. 2009 Nov 17;101(10):1724-30. doi: 10.1038/sj.bjc.6605371. Epub 2009 Oct 27. Br J Cancer. 2009. PMID: 19861964 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JHM, Shapiro GI. Boss DS, et al. Among authors: morris c. Ann Oncol. 2010 Apr;21(4):884-894. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825886 Free PMC article. Clinical Trial.
4,302 results